Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Celularity and Fountain Life announced the availability of cenplacel-L for investigational use by licensed physicians in Florida under new state legislation. The Florida framework, effective July 1, 2025, allows physician-directed use of certain unapproved cell therapies, creating a scalable pathway for Celularity to deploy its placental-derived allogeneic therapy outside traditional FDA approval routes.
Key figures
- Drug Name
- cenplacel-L
- Effective date
- July 1, 2025
- Regulatory framework
- Florida Statutes § 458.3245 and § 459.0127
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.